Free Trial
NASDAQ:BIOL

BIOLASE (BIOL) Stock Price, News & Analysis

BIOLASE logo

About BIOLASE Stock (NASDAQ:BIOL)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
2.58 million shs
Market Capitalization
$581 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BIOLASE, Inc. is a dental technology company known for developing and marketing laser systems for dental procedures. Its products are designed for use by general dentists and dental specialists in a range of clinical applications.

Its product portfolio has included Waterlase systems, which use a combination of laser energy and water, and diode laser systems marketed under the Epic brand. The company has also offered related accessories, training and support services for dental professionals.

Founded in 1984, BIOLASE has served dental markets in the United States and internationally, including through distributor relationships. The company filed for Chapter 11 bankruptcy protection in 2024, so its historical product portfolio should not be taken as a guarantee of current availability.

AI Generated. May Contain Errors.

Receive BIOL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIOL Stock News Headlines

A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
See More Headlines

BIOL Stock Analysis - Frequently Asked Questions

BIOLASE, Inc. (NASDAQ:BIOL) announced its quarterly earnings results on Wednesday, November, 10th. The medical technology company reported ($50.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($75.00) by $25.00. The medical technology company had revenue of $9.53 million for the quarter. BIOLASE had a negative trailing twelve-month return on equity of 1,782.73% and a negative net margin of 41.65%.

BIOLASE's stock reverse split on the morning of Friday, July 28th 2023.The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that BIOLASE investors own include Zomedica (ZOM), Bionano Genomics (BNGO), Tonix Pharmaceuticals (TNXP), SNDL (SNDL), NIO (NIO), Ocugen (OCGN) and Senseonics (SENS).

Company Calendar

Today
11/15/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:BIOL
Previous Symbol
NASDAQ:BLTI
CIK
811240
Employees
160
Year Founded
1987

Profitability

EPS (Trailing Twelve Months)
($14.94)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$20.63 million
Net Margins
-41.65%
Pretax Margin
-41.56%
Return on Equity
-1,782.73%
Return on Assets
-55.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.71
Quick Ratio
0.36

Sales & Book Value

Annual Sales
$48.83 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.07) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
33,407,000
Free Float
33,317,000
Market Cap
$581 thousand
Optionable
Not Optionable
Beta
0.67

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:BIOL) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners